Oestrogen receptors (ERs) and b-adrenergic receptors (bARs) play important roles in the cardiovascular system. Moreover, these receptors are expressed in cardiac myocytes and vascular tissues. Numerous experimental observations support the hypothesis that similarities and interactions exist between the signalling pathways of ERs (ERa, ERb and GPR30) and bARs (b 1 AR, b 2 AR and b 3 AR). The recently discovered oestrogen receptor GPR30 shares structural features with the bARs, and this forms the basis for the interactions and functional overlap. GPR30 possesses protein kinase A (PKA) phosphorylation sites and PDZ binding motifs and interacts with A-kinase anchoring protein 5 (AKAP5), all of which enable its interaction with the bAR pathways. The interactions between ERs and bARs occur downstream of the G-protein-coupled receptor, through the G as and G ai proteins. This review presents an up-to-date description of ERs and bARs and demonstrates functional synergism and interactions among these receptors in cardiac cells. We explore their signalling cascades and the mechanisms that orchestrate their interactions and propose new perspectives on the signalling patterns for the GPR30 based on its structural resemblance to the bARs. In addition, we explore the relevance of these interactions to cell physiology, drugs (especially bblockers and calcium channel blockers) and cardioprotection. Furthermore, a receptor-independent mechanism for oestrogen and its influence on the expression of bARs and calcium-handling proteins are discussed. Finally, we highlight promising therapeutic avenues that can be derived from the shared pathways, especially the phosphatidylinositol-3-OH kinase (PI3K/Akt) pathway. 
cardiovascular system (CVS). There are 3 classes of ERs: the ERa, ERb and the G-protein-coupled receptor 30 (GPR30). All these ERs are expressed in the heart cells and in the vascular vessels. [2] [3] [4] [5] Each receptor subtype shows variation in function and in tissue-specific expression. Based on ligand specificity, oestrogen and some of its metabolic intermediate products activate the ERs triggering both genomic and nongenomic actions. 6 Results from several experiments have implicated oestrogen in the chronotropic and inotropic functions of the heart, 7-9 and in cardiac perfusion. [10] [11] [12] In their recent study, Debortoli et al. 10 showed that activation of GPR30 modulated coronary circulation by regulating coronary perfusion pressure in rats. Accordingly, left ventricular diastolic dysfunction is predominant in post-menopausal women. 13 Consistent with these reports, Giraud et al. 14 
used
Magness et al.'s menopause model 15 and showed that left ventricle diameters and end-diastolic volume were elevated by chronic oestrogen replacement in this model. In the ovine model, 3 research groups showed that 17b-oestradiol administration increased coronary blood flow significantly. [15] [16] [17] [18] [19] [20] Collectively, they showed that the pattern of rises in coronary perfusion is independent of patterns of rises in cardiac output. They also noted that the pattern of raises in cardiac output was graded, that is a 30-to 60-min delay followed by an increase and a plateau at 90-120 minutes, a phenomenon observed in reproductive tissues such as uterus and mammary gland. 15, 20 Mershon et al. confirmed that these effects of oestrogen are ER-dependent as they were prevented by pretreatment with antagonist ICI-182 780. 18 The heart rhythm and contraction are mainly regulated by the sympathetic nervous system (SNS), via the b-adrenergic receptors (bARs) that connect and convey the SNS signals to the heart. bARs are divided into b 1 AR, b 2 AR and b 3 AR. 21 Interestingly, signalling pathways of ERs are intertwined with those of the bARs pointing to the possibility of functional convergence in modulating the physiology of the CVS. In fact, crosstalk between ERa and a 1b -adrenergic receptor was reported previously. 22 -ATPase (SERCA) and ryanodine receptors (RyRs; Figure 1 ). 27 Consequently, the effects of oestrogen on the Ca 2+ -handling proteins have direct implications on the contractile machinery of the myocardium.
In recent decades, the need to understand the cardiovascular functions of oestrogen and bARs has received much interest from researchers. The discovery of GPR30, 28 which shares structural features with bARs, has expanded the functional scope of oestrogen. In this regard, it is important to re-evaluate the relationships between ER and bAR signalling pathways and their interdependence in modulating the cardiovascular physiology. This review focuses on the recent experimental studies to describe the roles and mechanisms of ERs and bARs. We firstly discuss their classification, functions and the basis of cardiac physiology. We then provide novel illustrations on the points of integration between oestrogen and adrenergic signalling pathways. Our aim is to provide evidence for the hypothesis that there are interactions and functional cooperation between ER and bAR signalling pathways, particularly in the heart. We highlight the therapeutic potential of the interactions and explore their implications on the postulated cardioprotection conferred by oestrogen, b-blockers and Ca 2+ channel blockers. We also discuss the ERs and bARs as coregulators of cardiac Ca 2+ -handling proteins.
| A RECAP OF b-ADRENERGIC

RECEPTORS IN THE CARDIOVASCULAR SYSTEM
2.1 | bAR-specific features bARs are members of the G-protein-coupled receptors (GPCRs) that classically form 7 transmembrane loops, with extracellular and intracellular terminals. Three bAR subdivisions, b 1 AR, b 2 AR and b 3 AR, are encoded by different genes. 21 Moreover, the 3 receptors are expressed in the plasma membrane in the CVS, 29 as well as in the cardiac nuclear envelope of adult rats and mouse myocytes for b 1 AR and b 3 AR. [30] [31] [32] In heart myocytes, the number of b 1 ARs is higher than that of b 2 ARs, while b 3 ARs show the least abundance. 33 bARs are linked to heterogeneous intracellular signalling pathways and proteins. In addition, their expressions vary under physiological and pathological conditions. 34 2.2 | bAR-specific signalling bARs are activated by noradrenaline and adrenaline released from the SNS and adrenal glands respectively. However, once activated, the bARs trigger diverse intracellular pathways. 35 b 1 ARs couple to the stimulatory unit of the G protein (G as ) leading to the synthesis of cyclic adenosine monophosphate (cAMP) by adenylyl cyclase (AC) enzyme. On the other hand, b 2 ARs are pleiotropic receptors that couple to the G as , the inhibitory G protein (G ai ) and the G bc . 36, 37 At the physiological state, b 2 ARs couple to the G as , whereas at high adrenaline concentration, they switch to G ai , a phenomenon referred to as stimulusmediated trafficking. 38, 39 Activation of the b 2 AR/G ai pathway inhibits cAMP production, an opposing effect to b 2 AR/G as and b 1 AR/G as activation (Figure 1 ). With regard to structure and function, the b 3 ARs display distinct differences to b 1 ARs and b 2 ARs. Notably, the cytoplasmic C-terminus of the b 3 ARs lacks the target amino acid sequences for protein kinase A (PKA) and cardiac G-protein-coupled receptor kinase 2 (GRK2) phosphorylation. 40, 41 Consequently, b 3 ARs are less susceptible to PKA/GRK2-mediated receptor recycling and desensitization in response to hyperstimulation. 40 Two isoforms, b 3a AR
and b 3b AR, were reported in Chinese hamster ovary (CHO) cells and 3T3-L1 adipocytes. [42] [43] [44] [45] [46] The b 3a AR isoform coupled to the G ai , whereas b 3b AR coupled to both G as and G ai . At present, there are no reports regarding the existence of the 2 isoforms in human cardiac cells. b 3 AR has largely been associated with metabolic functions. Nevertheless, b 3 AR stimulation induced positive inotropy in human atrial cells, 47 but it had no effect on the inotropy of human ventricular cells. 48 b 3 AR may influence chronotropic functions through the nitric oxide (NO)/guanosine 3 0 ,5 0 -monophosphate (cGMP) pathway. 49 Activation of plasma b 3 AR-NO synthase/guanylyl cyclase pathway was shown to influence the nuclear b 3 AR-mediated gene transcription, suggesting a crosstalk between the surface and nuclear b 3 ARs. 50 2.3 | The basis of the heart's function bARs mediate the SNS regulation of the cardiac functions. 51 These functions are primarily orchestrated by activation of b 1 ARs, which constitute up to 80% of the entire cardiac bAR density of healthy human, and to a lesser extent by the b 2 ARs. 33, 35 Moreover, b 2 ARs have a higher affinity for adrenaline, while b 1 ARs have almost equal affinities for both noradrenaline and adrenaline. 39 On the other hand, activation of the b 3 ARs is largely associated with negative inotropy during catecholaminergic stress. 47 Once activated, bARs initiate cAMP synthesis by coupling to the G as , a GTP-binding protein. This cAMP, in turn, activates PKA. What follows is the induction of intracellular rise in Ca 2+ transients via the tightly regulated network of ion channels. PKA-mediated inotropic effects are orchestrated through the phosphorylation of 2 main channels: the LTCC located in the T-tubular network formed by sarcolemmal membrane invaginations and the RyR2 receptors on the SR membrane. Phosphorylation of LTCC [60] [61] [62] In addition, there are controversies surrounding the cellular localization of GPR30. In particular, some researchers reported that GPR30 was nearly confined to the endoplasmic reticulum in COS cell lines, 63 while others observed both cytosolic and membrane localization in HEK293 cells 64 and in rat
VSMCs. 65 The differences in these reports may be related to tissue-specific variations. It is also important to note that oestrogen is a lipophilic hormone that crosses the plasma membrane to access the intracellular receptors. Therefore, both membrane and subcellular localization of GPR30, as observed, are conceivable as they are accessible to oestrogen.
With regard to gender, a study carried out on VSMCs of rats showed that GPR30 expression was similar in both males and females. 65 However, gender differences with regard to ERa and ERb expression were also reported. Whereas the mRNA levels of ERa were equivalent in hearts of both men and women, 3, 66 ERb had greater expression in males than females in both healthy and diseased human hearts. 67 However, these observations are in contradiction to another report that showed an opposite expression pattern where ERb expression was not different in male and female cardiomyocytes, while ERa expression varied with gender. 68 Elsewhere, ERa and ERb protein levels in male and female rabbit hearts were not different. 69 Further studies are advocated to reconcile these findings. In addition, Ma et al. 65 observed that subcellular location of ERa was not influenced by its activation; a similar observation was reported for GPR30 in a subsequent study. 64 However, change in subcellular location of the ERs may vary as in heart failure. In healthy hearts, ERa was localized to the intercalated disc, while in failing hearts, its location shifted away from the intercalated discs. 66 This implies that cardiomyopathies may influence the subcellular localization and by extension the signalling of the ERs. Moreover, oestradiol supplementation in ovariectomized (OVX) rats increased ERa and ERb protein levels. 70 Variation in relative abundance of the ERs was recently reported. Quantitative real-time PCR analysis of male mouse ventricle found that GPR30 mRNA levels were thrice those of ERa and 17-fold greater than those of ERb. 62 Different genes located on different chromosomes encode each ER subtype. While alternative splicing of the gene transcripts leads to multiple subtypes of ERa and up to 5 described transcripts of ERb, 71 GPR30 only exists in 1 isoform. 3, 6, 72 The distinct features of the ER subtypes are outlined in Table 1 . Taken together, expression of the ER subtypes in the cardiovascular system remains contentious with regard to tissue-specific expression. Discrepancies from the previous reports could be due to the methods used or species of tissue investigated. Further investigations are required to resolve the inconsistencies.
| ER ACTIVATION, SIGNALLING PATHWAYS AND CELL FUNCTIONS
| ER activation
Similar to other steroids hormones, oestrogen signalling is initiated by the binding of 17b-oestradiol or xenoestrogens 73 and oestradiol metabolites 74, 75 to ER. Synthetic receptor-specific agonists with selective binding affinities have also been developed: propylpyrazoletriol (PPT) for ERa, diarylpropionitrile (DPN) for ERb and G1 for GPR30. 76 Noteworthy, each receptor subtype or isoform displays different affinities to 17b-oestradiol and other oestrogenic ligands. 77, 78 Moreover, oestrogens are of different forms (estrone, oestradiol and estriol) which exist in a dynamic equilibrium in circulation. Considering that oestrogen activates multiple receptors, ER subtype-specific functions determine cellular responses to oestrogen stimulation. It has been postulated that the balance between oestrogen forms is responsible for activation of different signalling pathways under certain physiological conditions based on the premise that ERs possess different affinities for each oestrogen subtype. 78 Furthermore, 17b-oestradiol synthesis occurs through enzymatic modifications of precursors such as androgens by aromatase enzyme. Considering that aromatase is expressed within the heart, 68 the possibility of cardiac oestrogen synthesis further augments the importance of oestrogen to the cardiovascular physiology in addition to circulating oestrogens. It is also likely that the adipose tissue surrounding the heart is the source of the C19 androgen conversion to C18 oestrogen, considering that epicardial fat covers up to 80% of heart's surface and constitutes 20% of heart's weight. Binding of oestrogen to its receptors (membrane or nuclear) triggers 2 types of cellular effects defined by the timing of onset. (i) Part of the effects occurs through the well-established pathway of ER-mediated transcription of certain genes. Conventionally, this pathway is known as a genomic pathway and occurs within hours to days. 80 The
ERa and ERb receptors largely execute these genomic functions. Upon oestrogen binding, these ERs undergo conformational changes allowing nuclear translocation and dimerization of the oestrogen-ER complex with oestrogen response elements, found at promoter areas of specific genes. Through this mechanism, oestrogen influences expression of cellular proteins. However, this pathway is not exclusive to nuclear receptors. Activation of membrane receptor GPR30 induced gene transcription. 4 (ii) Another pathway that emerges after oestrogen binding is the non-genomic pathway. This pathway requires activation of several different signalling cascades that alter cellular functions of proteins and ion channels. Most of these actions occur within seconds or minutes and are regulated by ERa and GPR30. 7, 62, 81 There are reports indicating the presence of ERb in the cytosol and plasma membrane and that they are responsible for rapid non-genomic signalling in endothelial cells. It is yet to be established whether ERb exists on the plasma membrane of adult cardiomyocytes. 60, [82] [83] [84] In addition, crosstalk between membrane ERs and nuclear ERs has been reported. 85 There is growing interest to decipher mechanisms that underlie non-genomic oestrogen signalling. How the non-genomic oestrogen pathways integrate with bAR pathways forms the basis of the discussion dealt with in Section 5 of this article. Moreover, the interaction of ER signalling with adrenergic receptor pathways was observed between the ERa and a 1b -adrenergic receptors. 
| Receptor-independent signalling
Besides the conventional receptor-mediated mechanisms of oestrogen, experimental observations have hinted at the possibility of an alternative mechanism that does not involve membranous or nuclear ERs. 81, 86, 87 This mechanism falls in the category of rapid and non-genomic pathways and does not involve oestrogen-receptor binding. A previous experiment showed that oestrogen induced negative inotropy in ERa and ERb knockout mouse cardiomyocytes and its inhibition of the LTCC current was not altered from wild-type myocytes. 88 The same laboratory later demonstrated that oestrogen directly interacts with the LTCC protein and inhibits LTCC current even at resting state on cultured HEK293 cells. 86 Indeed, similar observations have been reported for a broad range of ion channels (see review 89 ). Research on the rapid non-genomic roles of oestrogen has been primarily focused on the membranous receptors. Therefore, the observation that oestrogen could bind directly to ion channels introduces a reclassification of its mechanism of actions and adds to the growing debate on its non-genomic functions.
| Tissue-specific functions
Oestrogen plays several functions in the CVS. Here, we highlight some of the cell-specific roles of oestrogen without much detail because of the limitation defined by the purpose of this review. Activation of GPR30 inhibited proliferation of rat cardiac fibroblasts and collagen synthesis in both in vivo and ev vivo settings. 4 These effects were attributed to oestrogen-induced expression of cell cycle proteins and alterations in expression of matrix metalloproteinase-12. GPR30 also mediates cardioprotection against ischaemia/reperfusion injury by improving the heart function, reducing infarct size, and mitochondrial Ca 2+ overload. 62 On the other hand, ERa agonists induced vasodilation on vascular smooth muscle cells of the aorta. 90 In our previous study, we demonstrated that oestrogen and G1 decreased the expression of b 1 ARs and induced negative inotropy. 24, 91 ERb has also been reported to offer cardioprotection in cardiomyocytes. 92 Together, these findings demonstrate that ERs are important effectors of oestrogen signals in cardiovascular tissues.
| SIMILARITY IN MOLECULAR PATHWAYS OF ERS AND ΒARS
The crosstalk between ERs and bARs is a concept that was revealed from earlier studies. Additional interactions are possible due to the structural resemblance between GPR30 and bARs. bARs interact with cellular proteins through PDZ motifs located at their C-terminus regions. The PDZ motifs give a bearing on the localization and signalling of bARs. Of note, b 1 AR, b 2 AR and GPR30 possess type I PDZ binding motifs: -ESKV, -DSLL and -SSAV respectively.
106,107 PDZ domains recognize and bind to specific amino acid sequences of their target proteins. 106 For instance, the b 1 AR (-ESKV) motif was shown to be a determinant factor for its coupling to G as and not G ai . Induced disruption of this motif permitted b 1 AR/G ai coupling. 106 On the other hand, b 2 AR (-DSLL) motif plays a role in its coupling to G ai . 108 In comparison, the GPR30 PDZ motif (-SSAV) was implicated in recycling and translocation of GPR30 in HEK293 cells, 64 but it is not known whether this motif may influence GPR30's ability to couple to G as or G ai . In addition to the PDZ motifs, b 2 AR phosphorylation by PKA influences its ability to bind G as or G ai . 39 Although GPR30 coupling to G as or G ai may be dependent on cell/tissue type, collectively, these observations raise the possibility that PKA phosphorylation or disruption of its PDZ motif would have implications on its coupling to G as and G ai as is the case for b 1 ARs and b 2 ARs. This possibility calls for further inquiry to the conditions under which GPR30 couples to G ai and G as , and the proteins that interact with its PDZ motif. One functional implication of this motif draws from the recent observation that GPR30 inhibited bAR-mediated production of cAMP in response to isoproterenol stimulation in HEK293 cells. 64 This inhibitory effect was dependent on a complex formed by GPR30, through its PDZ motif, with membrane-associated guanylate kinases (MAGUKs) and AKAP5 (Figure 2) . 64 The primary role of GPR30/PI3K/Akt-mediated cardioprotection against ischaemia/reperfusion injury in cardiomyocytes was orchestrated through upregulation of anti-apoptosis Bcl-2 protein and downregulation of pro-apoptosis Bax protein. 116 In accordance with our previous report, inhibition of b 2 ARs exposes cardiomyocytes to cell death in ischaemic conditions. 117 The b 2 AR/G ai pathway triggered anti-apoptotic signals through the PI3K/Akt pathway. 118 These findings present the evidence that PI3K/Akt cardioprotective pathway is shared by the GPR30 and b 2 ARs. In addition to the GPR30, oestrogen activates the ERa, which directly binds the p85 alpha regulatory component of the PI3K. 119 In addition, PKA phosphorylation of the b 2 ARs enables switching of its coupling from G as to G ai under extreme catecholamine stimulation, 39 a phenomenon referred to as signal trafficking (Figure 1 ERβ PKA P P P P P P P PK P P P P P P P P P P P P P P P P P P P P P P P P P P P P P A CaMKII C C C C C C C CaM G ai /PI3K/Akt pathways in the cardiovascular system. Similarly, both GPR30 and ERa signalling cascades interact through the PI3K/Akt pathway ( Figure 1 ). PI3K/Akt acts as a focal pathway that unifies GPR30-, ERa-and b 2 ARmediated cardioprotection. In general, the G as /AC/cAMP and G ai /PI3K/Akt pathways seem to trigger opposing effects. For example, the cAMP produced by bAR stimulation was shown to inhibit the activity of Akt kinase indicating an inverse relationship between the 2 pathways. 124 Lastly, the net cellular effects of the interactions between ERs and bARs might be dependent on the cell/tissue type. , 128 while caveolin 3 interaction with AC V acts as a scaffolding protein which participates in b 1 AR signals that induce LTCC current in ventricular cardiomyocytes. 129 ERa was associated with eNOS activation in the caveolae of endothelial cells, 130 while ERb was found in the caveolae where it mediated eNOS signals. 82 Strikingly, overexpression of b 2 AR enhanced vascular repair of endothelial progenitor cells in mice through the eNOS pathway. 131 Therefore, localization of b 2 AR and ERb in caveolae of vascular cells and their ability to signal through the eNOS pathway indicate functional cooperation between the 2 receptors. Caveolin 1 is a scaffold protein for both ERa and b 3 AR.
| Localization of ERs and
132,133
The association of b 3 AR with caveolin 1 was shown to govern its ability to couple to G ai/o proteins in CHO-K1 cells. 133 On the other hand, it has been established that ERa and ERb interact directly with G ai and that these interactions occur in close proximity to the caveolae domains. 134 The physiological relevance of the possible interactions among ERs, caveolins and bARs in adult cardiomyocytes remains to be fully established. Although there is a dearth of evidence regarding this view, the data sets reviewed here imply direct or indirect crosstalk among ERs and bARs. Further research is required to identify multilevel communications and interactions among these receptors. A summary of the shared features is as follows: 
| OESTROGEN INFLUENCE ON THE EXPRESSION OF bARS
Expression of bARs in the cardiovascular vessels is influenced, in part, by age, by gender and by drugs targeting these receptors. 135 The ratio of b 1 ARs, b 2 ARs and b 3 ARs may also vary with disease status. 136 In pre-menopausal women, the cardiac expression of b 1 ARs and b 2 ARs decreases with age until menopause after which it stabilizes. 135 On the contrary, there is no significant association between age and b 1 AR/b 2 AR expression in men. 135 Together with other numerous animal experiments, these observations seem to indicate that sex hormones, particularly oestrogen, play regulatory roles in the expression of bARs. Moreover, these roles may be due to the direct action of oestrogen on bAR signalling cascades or indirectly through adaptative responses to oestrogen environment.
| b 1 AR expression
Our studies 91 and others 25, 137, 138 systematically showed that ovariectomy (OVX) increased the expression of b 1 ARs and induced negative inotropy in rat hearts subjected to ischaemia/reperfusion injury (I/R) and, in addition, that this role of oestrogen was mediated by the ERa. 91 On the other hand, activation of GPR30 in ventricular myocytes from OVX rats reversed the effects of OVX on b 1 AR expression. 24 Taken together, these findings indicate that oestrogen-mediated influences on b 1 AR levels are affected by both ERa and GPR30. Furthermore, it was shown that oestrogen not only suppressed the expression of b 1 ARs but also increased sensitivity to catecholamines. 139 Therefore, the downregulation of b 1 ARs by oestrogen may be a cardioprotective strategy against the adverse effects associated with hyperstimulation of b 1 ARs.
| b 2 AR expression
In female rat models of I/R and heart failure, oestrogen, acting through the GPR30 24 and ERa, 91 increased the expression of b 2 ARs. We further showed that oestrogen in combination with testosterone enhanced the cardiac expression of b 2 ARs in OVX rats. 140 Other researchers also reported that b 2 AR mRNA and protein were upregulated in female hearts but not male hearts in response to the arteriovenous fistula procedure. 141 Taken together, these observations show that oestrogen decreases b 1 AR expression and upregulates b 2 AR expression in cardiac cells.
| b 3 AR expression
Currently, information on direct effects of oestrogen on b 3 AR expression in cardiac tissues is lacking. However, variations in expression of b 3 ARs in adipose tissues have been linked to oestrogen levels. One group reported that oestrogen elevated the expression of b 3 ARs in murine adipocytes in culture, 142 while another group observed that oestrogen decreased the quantity of b 3 ARs in brown adipose tissue of female rats in vivo. 143 The discrepancies in these reports might be attributed to the methodologies used, that is real-time PCR vs. radio-ligand binding method used in the latter report or due to the inherent differences between in vitro and in vivo studies. (Figure 1) . 144 In addition to the major proteins LTCC, RyR, PLB, SERCA and NCX, 27 sarcolipin (SLN), an inhibitor of SERCA, plays a role in cardiac Ca 2+ handling. 145 However, to our knowledge, the influence of oestrogen on the expression or function of SLN has not been documented and hence needs to be clarified. The results of previous studies that were designed to investigate the effect of oestrogen on expression of cardiac Ca 2+ -handling proteins channels are summarized in Table 2 . In summary, the reports on oestrogen regulation of SERCA were largely consistent that oestrogen increased expression of SERCA, while its expression was decreased in OVX animal models 92, 93, [146] [147] [148] (full reference list in Table 2 ). Similarly, oestrogen increased expression of NCX, 26, [149] [150] [151] while it was decreased in OVX rats. 26 However, in other studies, no change was observed in the expression of NCX expression in both oestrogen treatment and OVX animals. [152] [153] [154] Although oestrogen decreased the expression of PLB, [155] [156] [157] and OVX increased its expression, [155] [156] [157] [158] no change in expression was found in other reports. 26, 147, 153, 159, 160 On the other hand, oestrogen downregulated the RyR expression, 161 while in other reports both OVX and oestrogen treatments had no effect on RyR expression. 26, 153 Similarly, studies examining the role of oestrogen on the expression of LTCC yielded mixed results. Oestrogen decreased LTCC protein levels in rat ventricular myocytes (RVMs), 26, 161 while OVX increased its expression in RVMs, 26 but decreased its expression in mouse ventricular myocytes. 154 These studies were carried out in different animal species, disease models, tissue/cell types, age groups, in vivo and ex vivo and using different oestrogen types. Moreover, the observed changes in protein expression due to OVX were reversed by oestrogen replacement. 26, 147, 155, 162 This implies that the discrepancies between some of the results could be a result of the experimental variations, and hence, head-to-head comparisons might not be possible. 163 These drugs control the heart rate and blood pressure by modulating the activation of bARs. However, there are conflicting observations regarding their effectiveness in managing conditions such as hypertension. 163 Reports from cohort studies have noted that some patients, particularly women, under b-blockers are unable to reach targeted blood pressure compared to men. 164 This observation can be explained, partially, by the aforementioned influence of oestrogen on bARs' function. Moreover, gender and age differences in expression of b 1 ARs/ b 2 ARs have been reported, which may be attributed to oestrogen. 135 Besides, gender variations in responses to catecholamines, 139 and in cardiac Ca 2+ handling, 165 have been observed in animal experiments. Therefore, the efficacy of b-blockers and Ca 2+ blockers may vary with gender or age groups based on the interplay between ERs and bARs. As demonstrated, carvedilol, a non-selective b-blocker, protected against myocardial contractile dysfunction caused by oestrogen deficiency. 158 Interestingly, this is one of the bblockers to display biased agonism and it too can activate the b 2 AR-G ai /b-arrestin pathways. 166, 167 With the current understanding of the ER and bAR pathways, further studies should examine how the efficacy of the drugs targeting these receptors and/or their signalling pathways may be altered in the context of the ER and bAR crosstalk. Theoretically, oestrogen by inhibiting the LTCC or altering the expression of bARs might indirectly compromise the functions of Ca 2+ blockers and b-blockers respectively. Consequently, men and women may respond differently to these classes of drugs. The crosstalk may inform the decisions regarding the choice of antihypertensive drugs to patients with consideration to age and gender.
| Therapeutic opportunities
The functional synergism between ERs and bARs provides therapeutic avenues for cardioprotection. For example, while b 1 AR activation promotes CaMKII-induced act in a manner that promotes anti-apoptosis through the G i /PI3K/Akt pathway. Considerations for strategies targeting the PI3K/Akt pathway will provide a feasible avenue for cardioprotection. For instance, the ability of ERa binding to the alpha subunit of PI3K seems attractive, as it is more specific and avoids various points of integration between ER and bAR signalling cascades discussed above. Activation of Akt pathway will protect against mitochondria-associated apoptosis induction. Moreover, Akt was shown to act as a surrogate molecular ligand for ERa that induced expression of oestrogen-regulated cardioprotective genes in breast cancer cells. 168 This perspective partly indicates that selective activation of this pathway would potentially enhance the cardiac functions under pathological conditions. Another therapeutic target is the possibility of direct binding of oestrogen to the LTCC. Oestrogen-LTCC docking studies may help to predict the mode of binding/ interaction of this complex. This approach will advance the prospects of oestrogen as a Ca 2+ channel blocker if appropriate technologies are applied to enhance its specificity. We anticipate that the therapeutic value of this manoeuvre could be a potential target for Ca
2+
-related pathologies such as arrhythmia treatments.
| CONCLUSION
This review demonstrates the expression patterns and functions of ERs and bARs in cardiovascular tissues. The data sets reviewed above show some inconsistencies with regard to tissue-specific expression of the ERs. For instance, it is not clear whether ERb is expressed in adult cardiomyocytes, and the cellular localization of GPR30 is not clear. Therefore, further studies are warranted to resolve these observations. In addition, the reviewed data sets strongly support the hypothesis that ERs and bARs function as collaborative partners in modulating the physiology of the cardiovascular system. The recently described oestrogen receptor GPR30 mimics the dual coupling of the b 2 ARs to the G as and G ai proteins. On this basis, oestrogen pathways play into the network of the bAR signalling cascades. Furthermore, GPR30 and bARs show similarities with regard to their ability to associate with AKAPs, PDZ motif-binding proteins and possession of PKA and CaMKII binding sites. Despite the signalling pathways discussed in this review, the functions of the GPR30 and other ERs remain incompletely understood. Further research is required to uncover the identities of signalling molecules that orchestrate their functions.
The crosstalk between the ERs and bARs could have implications on drugs that target these receptors, especially b-blockers and Ca 2+ channel blockers. Oestrogen influences the expression of bARs and Ca
2+
-handling proteins, which could compromise the efficacy of the drugs in a gender-dependent manner. This perspective requires further evaluation at the clinical level. In addition, the concept of direct oestrogen binding to the LTCC might be of great clinical relevance as oestrogen might be used to design Ca 2+ channel blockers. This opens a window of research into the receptor-independent pathways for oestrogen. Furthermore, future research should exploit the therapeutic potential of the cardioprotective PI3K/Akt pathway that is activated downstream of both ERs and bARs.
